SOURCE: Kendall Law Group

Kendall Law Group

August 11, 2009 16:42 ET

Kendall Law Group Announces Class Action Against Repros Therapeutics, Inc.

DALLAS, TX--(Marketwire - August 11, 2009) - Kendall Law Group, led by a former federal judge and former US Attorney, announces that a class action against Repros Therapeutics, Inc. (NASDAQ: RPRX) was filed one week after the company suspended clinical trials for its Proellex drug. The lawsuit, filed in the Southern District of Texas, represents a class of investors who purchased RPRX stock between January 1, 2009 and July 31, 2009.

If you wish to serve as lead plaintiff, you must move the Court for appointment by October 6, 2009. Although your ability to share in any recovery is not affected by the decision whether or not to seek appointment as a lead plaintiff, lead plaintiffs make important decisions which could affect the overall recovery for class members.

Repros Therapeutics is a biopharmaceutical company that focuses on the development drugs concerning reproductive disorders. On August 3, 2009, Repros announced that it was suspending the use of Proellex in clinical trials due to adverse events that were more serious than the company had previously reported. As a result of this announcement, Repros stock fell more than 48%, closing at $1.31 per share on August 3, 2009 with unusually high trading volume.

For information about your rights as a Repros Therapeutics shareholder, contact attorney Hamilton Lindley at 877-744-3728 or by email at Kendall Law Group is led by a former federal judge and former U.S. Attorney. The firm has nationwide experience representing investors in securities litigation.

Contact Information